Ruxolitinib therapy decreases serum levels of inflammatory cytokines and chemokines in infected Prf1^−/− mice. Serum levels of IFN-γ and CXCL10, and (B) serum levels of IL-6, TNF-α, MCP1, and sCD25 were measured at different points (on days 7, 10, and 28) in control (B6) and Prf1^−/− mice nontreated, treated with ruxolitinib from day 7 postinfection for 14 days, or treated with anti-IFN-γ antibody from day 7 until day 16. Data (mean ± SEM) are representative of 2 to 3 independent experiments with at least 3 mice in each group. *P < .05; **P < .005; ***P < .001; ****P < .0001.